Gene Therapy · us
Early data for cardiac gene therapy LX2020: NSVT burden falls by an average of 80% in 7 high-dose participants
Can replacing the PKP2 gene gradually quiet the dangerous rhythms of inherited cardiomyopathy? A small trial reported by Lexeo showed signs of improvement, and the company has begun exploring an accelerated approval pathway. Whether fewer arrhythmias mean lower long-term risk, however, remains unproven.
For patients with PKP2-related arrhythmogenic cardiomyopathy, the goal of treatment is not simply to ease palpitations, but also to reduce the risk of potentially life-threatening heart rhythms. On November 16, Lexeo Therapeutics announced interim Phase 1/2 results for its gene therapy LX2020: among 7 participants who received the high dose, the burden of nonsustained ventricular tachycardia (NSVT) at the latest assessment fell by an average of 80% from before treatment. This is a preliminary efficacy signal and does not yet establish that the therapy can prevent sudden death.
This inherited disease stems from a loss of PKP2 gene function, which affects connections between heart muscle cells and may be accompanied by the gradual replacement of heart muscle with fat and fibrous tissue. Current care focuses on controlling arrhythmias and preventing sudden death. LX2020 uses an adeno-associated virus (AAV) vector to deliver a functional PKP2 gene into heart muscle cells, attempting to address the defect in cellular connections. Whether this approach can alter the course of the disease is the question being tested in human trials.
The trial, called HEROIC-PKP2, has a single-arm, open-label design. A total of 10 participants received treatment: 3 at the low dose and 7 at the high dose. The study plans a 52-week primary observation period, followed by an additional 4 years of long-term follow-up. As of October 15, 2026, 9 participants had been followed for at least 12 months and 1 for 9 months, meaning the “latest assessment” was not at the same time point after treatment for everyone.
In the high-dose group, 6 participants had a reduction in NSVT burden, while premature ventricular contraction burden also fell by an average of 44%. The company's presentation further noted that, among the 6 high-dose participants who completed the 12-month assessment, 5 had fewer than one NSVT episode per day. A separate natural history study, SNAPSHOT, which included 15 participants, recorded a 53% increase in NSVT at 12 months. However, the two studies were not a randomized, concurrent comparison. Differences between participants and fluctuations in heart rhythms themselves limit the interpretation of this comparison.
On safety, the company said overall tolerability was acceptable, with no clinically meaningful complement activation and no withdrawals from the study. Elevated liver function test values occurred in the high-dose group and were managed according to the trial protocol, without complications or hospitalization. One participant also experienced a Grade 3 serious adverse event of ventricular tachycardia 3 months after dosing and was discharged after treatment with antiarrhythmic medication. The company considered the event consistent with the natural course of the disease, but the small trial remains insufficient to fully characterize the treatment's risks.
The update also addressed the direction of future regulatory review. According to Lexeo, the U.S. Food and Drug Administration (FDA) is open to exploring accelerated approval using NSVT, as defined by guidelines, as the primary surrogate endpoint. The company expects to finalize the pivotal trial design, statistical analysis plan, and strategy for evidence to confirm efficacy in the first half of 2027, and to initiate the trial in the second half. These plans remain subject to further discussion with the FDA and do not mean that either the therapy or the approval pathway has received final agreement.
NSVT consists of brief runs of rapid ventricular beats lasting less than 30 seconds and is also a clue used to assess the risk of subsequent serious arrhythmias. However, a reduction in a risk marker still needs to be shown to translate into an actual reduction in life-threatening events. The current data come from a company-reported, uncontrolled trial of 10 participants. More comprehensive studies and long-term follow-up will be needed to clarify how long this improvement lasts and whether it translates into actual benefits for patients.